Bavarian Nordic ASCHIX:BAVAC 84 Days Payable is 102.96 as of Mar. 2026, which is 4% below its 10-year median of 107.74. GuruFocus rates CHIX:BAVAC with a GF Score™ of 84/100 and a GF Value™ of kr174.21 (Fairly Valued). The stock has 2 warning signs investors should review. Among 705 Biotechnology companies, Bavarian Nordic AS ranks worse than 54.89% on this metric.
The historical rank and industry rank for Bavarian Nordic AS's Days Payable or its related term are showing as below:
CHIX:BAVAc'
s Days Payable Range Over the Past 10 Years
Min: 69.85 Med: 107.74 Max: 126.52
Current: 93.69
During the past 13 years, Bavarian Nordic AS's highest Days Payable was 126.52. The lowest was 69.85. And the median was 107.74.
CHIX:BAVAc's Days Payable is ranked worse than 54.89% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs CHIX:BAVAc: 93.69
Bavarian Nordic AS's Days Payable
declined
from Mar. 2025 (104.29) to Mar. 2026 (102.96).
It may suggest that Bavarian Nordic ASaccelerated paying its suppliers.
Bavarian Nordic AS Days Payable Related Terms
Bavarian Nordic AS Days Payable Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bavarian Nordic AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a Days Payable of 102.96 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bavarian Nordic AS and its competitors. This is near median its historical median of 107.74. Over the past decade, Bavarian Nordic AS's Days Payable has ranged from 69.85 to 126.52. According to the industry distribution chart, Bavarian Nordic AS ranks #387 out of 705 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Bavarian Nordic AS's Days Payable too high?
Bavarian Nordic AS's current Days Payable of 102.96 is near median its 10-year median of 107.74. Over the past 10 years, this metric has ranged from a low of 69.85 to a high of 126.52. The Biotechnology industry median Days Payable is 113.36. Bavarian Nordic AS's value of 102.96 is 9.2% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #387 out of 705 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #387 out of 705 companies for Days Payable. This places Bavarian Nordic AS in the lower half of its industry. The industry median Days Payable is 113.36. Bavarian Nordic AS's value of 102.96 is 9.2% below this benchmark. Historically, Bavarian Nordic AS's own Days Payable has ranged from 69.85 to 126.52 over the past decade. While the company's 10-year median is 107.74 vs. the industry median of 113.36, Bavarian Nordic AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Days Payable of 102.96 is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Days Payable is 102.96, which is near median its own 10-year median of 107.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Fairly Valued. The stock's GF Value™ is kr174.21, compared to a current price of kr188.30 — trading 8.1% above its estimated fair value. The current Days Payable is 102.96, which is near median its 10-year median of 107.74 and 9.2% below the Biotechnology industry median of 113.36. Bavarian Nordic AS's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Days Payable is 102.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 8.1% above its estimated GF Value™ of kr174.21.
GuruFocus considers Bavarian Nordic AS to be Fairly Valued.
Key valuation signals for CHIX:BAVAC:
Days Payable: 102.96 (near median its 10-year median of 107.74)
GF Value™: kr174.21 vs. price of kr188.30 (8.1% above fair value)
Industry Position: 9.2% below the Biotechnology median (#387 of 705)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
84GF Score
Get the complete analysis for CHIX:BAVAC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
